Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy

M. E. Pisanu, A. Ricci, L. Paris, E. Surrentino, L. Liliac, M. Bagnoli, S. Canevari, D. Mezzanzanica, F. Podo, E. Iorio, R. Canese

Research output: Contribution to journalArticlepeer-review


Background:Limited knowledge is available on alterations induced by cytostatic drugs on magnetic resonance spectroscopy (MRS) and imaging (MRI) parameters of human cancers, in absence of apoptosis or cytotoxicity. We here investigated the effects of a cytostatic cisplatin (CDDP) treatment on 1 H MRS and MRI of HER2-overexpressing epithelial ovarian cancer (EOC) cells and in vivo xenografts.Methods:High-resolution MRS analyses were performed on in vivo passaged SKOV3.ip cells and cell/tissue extracts (16.4 or 9.4 T). In vivo MRI/MRS quantitative analyses (4.7 T) were conducted on xenografts obtained by subcutaneous implantation of SKOV3.ip cells in SCID mice. The apparent diffusion coefficient (ADC) and metabolite levels were measured.Results:CDDP-induced cytostatic effects were associated with a metabolic shift of cancer cells towards accumulation of MRS-detected neutral lipids, whereas the total choline profile failed to be perturbed in both cultured cells and xenografts. In vivo MRI examinations showed delayed tumour growth in the CDDP-treated group, associated with early reduction of the ADC mean value.Conclusion:This study provides an integrated set of information on cancer metabolism and physiology for monitoring the response of an EOC model to a cytostatic chemotherapy, as a basis for improving the interpretation of non-invasive MR examinations of EOC patients.

Original languageEnglish
Pages (from-to)625-635
Number of pages11
JournalBritish Journal of Cancer
Issue number3
Publication statusPublished - Feb 4 2014


  • cisplatin
  • cytostatic drug
  • HER2
  • magnetic resonance spectroscopy
  • MRI
  • ovarian cancer
  • phosphocholine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy'. Together they form a unique fingerprint.

Cite this